Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
3.890
-0.140 (-3.47%)
Feb 21, 2025, 4:00 PM EST - Market closed
Lexeo Therapeutics Employees
Lexeo Therapeutics had 58 employees as of December 31, 2023. The number of employees increased by 34 or 141.67% compared to the previous year.
Employees
58
Change
34
Growth
141.67%
Revenue / Employee
n/a
Profits / Employee
-$1,493,034
Market Cap
128.67M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 58 | 34 | 141.67% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
LXEO News
- 6 weeks ago - Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 4 months ago - Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - GlobeNewsWire
- 6 months ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 7 months ago - Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further - Seeking Alpha